Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome.
OBJECTIVE
To test whether the follicular fluid (FF) concentration of anti-Mullerian hormone (AMH) is associated with oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome (PCOS) undergoing IVF.


METHODS
Prospective.


METHODS
Academic assisted reproductive technology program.


METHODS
Twenty-two samples of FF from 11 patients with PCOS who underwent IVF/ET were analyzed for AMH levels (group A). Twelve women with normal ovulatory cycles served as a control group (group B). The oocytes and preembryos were closely followed until ET.


METHODS
FF was obtained at oocyte retrieval for IVF/intracytoplasmic sperm injection. AMH levels were studied using immunoenzymometric assay.


METHODS
None.


METHODS
FF, AMH levels, oocyte maturation, fertility rate, and embryonic cleavage rate.


RESULTS
The mean FF AMH level was 57.3 +/- 79.5 pmol/mL in group A, compared with 70 +/- 120.14 pmol/mL in group B. In group A, the mean AMH level of good-quality embryos was 37.4 +/- 23.4 pmol/mL, compared with 61.9 +/- 102 pmol/mL in a the poor-quality subgroup. No significant correlation was observed between FF AMH levels and oocyte maturation, fertilization, or cleavage rate.


CONCLUSIONS
This study suggests that there is an association between FF AMH levels and the quality of embryos in patients with PCOS. However, owing to large variance and the number of participants, no statistical significance was reached. The degree of maturation of retrieved oocytes, as well as the success of fertilization, was not found to correlate with FF AMH.
Mashiach
Roy
R
IVF Unit, Department of Obstetrics and Gynecology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Amit
Ami
A
Hasson
Joseph
J
Amzalzg
Sagi
S
Almog
Beni
B
Ben-Yosef
Dalit
D
Lessing
Joseph B
JB
Limor
Rona
R
Azem
Foad
F
D000328:Adult; D054304:Anti-Mullerian Hormone / Q000032:analysis* / Q000378:metabolism; D047108:Embryonic Development / Q000502:physiology*; D005260:Female; D005306:Fertilization / Q000502:physiology; D005307:Fertilization in Vitro / Q000379:methods; D015571:Follicular Fluid / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D009865:Oocytes / Q000502:physiology*; D009866:Oogenesis / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D011237:Predictive Value of Tests; D011247:Pregnancy; D018873:Pregnancy Rate; D011379:Prognosis
D054304:Anti-Mullerian Hormone